Chairman of the Board
Erik Nerpin (Swedish, born 1961) joined PILA PHARMA in 2017 as Chairman of the Board due to his significant experience as business lawyer in corporate finance, M&A, corporate governance, board work and stock market matters.
Erik Nerpin is an Attorney (Advokat) and holds a law degree (Jur kand) from the University of Uppsala, Sweden (1990) and an LL.M. in International Banking Law from Boston University School of Law, USA (1992).
Erik Nerpin is specialized in corporate finance with 25 years of experience in financing and listing of early stage companies and has been advisor to numerous life science companies. He has also extensive experience from M&A, including significant transactions in the pharmaceutical sector such as U.S. Big Pharma Pfizer’s acquisition of Pharmacia in which he was legal advisor to Pfizer.
Erik Nerpin has also been legal advisor within other sectors, such as oil & gas and mining, and has for many years servedthe Lundin Group of companies, including Lundin Petroleum AB (domiciled in Sweden) and Lundin Mining Corp (domiciled in Canada), both listed on Nasdaq in Stockholm.
Erik Nerpin currently runs his own law firm, Advokatfirman Nerpin in Stockholm. He has previously been partner in Linklaters Advokatbyrå (previously named Lagerlöf & Leman Advokatbyrå) and Kilpatrick Townsend Advokatbyrå.
Erik Nerpin currently holds Director of the Boards positions in the Swedish companies Kancera AB (Chairman), Diamyd Medical AB (Chairman), Nicoccino Holding AB and Effnetplattformen AB, all companies listed on Nasdaq First North, Sweden. Further, he is Chairman and co-founder of the Blasieholmen Investment Group companies in Sweden.